Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease

Experimental and Molecular Pathology

Volumn 84, Issue 3, 2008, Pages 213-217

  Liu, Wei ^a   Feng, Weiwei ^a   Wang, Fang ^a   Li, Weimin ^a   Gao, Cheng ^a   Zhou, Baoguo ^a   Ma, Manling ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cardiac remodeling; Extracellular matrix; IL 17; OPG; RANKL

Indexed keywords

CARDIAC MYOSIN; COLLAGEN; EOSIN; GELATINASE A; GELATINASE B; HEMATOXYLIN; HYDROXYPROLINE; INTERLEUKIN 17; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN ANTIBODY; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL ISOLATION; CERVICAL SPINE DISLOCATION; CONTROLLED STUDY; FIBROBLAST; FIBROSING ALVEOLITIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; IMMUNIZATION; IMMUNOPATHOLOGY; IN VITRO STUDY; MALE; MYOCARDITIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; AUTOIMMUNE DISEASES; CELLS, CULTURED; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; INTERLEUKIN-17; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYOCARDITIS; MYOCARDIUM; MYOSINS; OSTEOPROTEGERIN; RANK LIGAND; RATS; RATS, INBRED LEW; RATS, WISTAR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SWINE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VENTRICULAR REMODELING;

RATTUS; SUS;

EID: 45849111384     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2008.02.004     Document Type: Article

References (24)

1. Balsini V., Mastropasqua M., Francucci C.M., and D'Erasmo F. Cardiovascular disease and osteoporosis. J. Endocrinol. Investig. 8 10 Suppl (2005) 69-72 Review
2. Bergman I., and Loxley R. Lung tissue hydrolysates: studies of the optimum conditions for the spectrophotometric determination of hydroxyproline. Analyst 94 120 (1969) 575-584
3. D'Armiento J. Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc. Med. 12 (2002) 97-101
4. Gogo Jr. P.B., Schneider D.J., Terrien E.F., Sobel B.E., and Dauerman H.L. Osteoprotegerin is not associated with angiographic coronary calcification. J. Thromb. Thrombolysis. 22 3 (2006) 177-183
5. Helske S., Kovanen P.T., Lindstedt K.A., Salmela K., Lommi J., Turto H., Werkkala K., and Kupari M. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur. J. Heart Fail. 9 (2007) 357-363
6. Hermann-Arnhof K.M., Kastenbauer T., Publig T., Novotny P., Loho N., Schwarz S., Koller U., and Fitzgerald R. Initially elevated osteoprotegerin serum levels may predict a perioperative myocardial lesion in patients undergoing coronary artery bypass grafting. Crit. Care Med. 34 1 (2006) 76-80
7. Kaden J.J., Bickelhaupt S., Grobholz R., Haase K.K., Sarikoc A., Kilic R., Brueckmann M., Lang S., Zahn I., Vahl C., Hagl S., Dempfle C.E., and Borggrefe M. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J. Mol. Cell. Cardiol. 36 1 (2004) 57-66
8. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., Santer P., Smolen J., Poewe W., and Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109 (2004) 2175-2180
9. Li Y., Kucuk O., Hussain M., Abrams J., Cher M.L., and Sarkar F.H. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res. 66 9 (2006) 4816-4825
10. Lincoln J., Lange A.W., and Yutzey K.E. Hearts and bones: shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development. Dev. Biol. 294 (2006) 292-302
11. Liu W., Li W.-m., Gao C., and Sun N.-l. Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. J. Autoimmun. 25 4 (2005) 258-263
12. Liu W., Gao C., Zhou B.G., and Li W.M. Effects of adenovirus-mediated gene transfer of ICOSIg and CTLA4Ig fusion protein on experimental autoimmune myocarditis. Autoimmunity 39 2 (2006) 83-92
13. Lubberts E., van den Bersselaar L., Oppers-Walgreeen B., Schwarzenberger P., Coenen-de Roo C.J., Kolls J.K., Joosten L.A., and van den Berg W.B. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J. Immunol. 170 5 (2003) 2655-2662
14. Mukherjee D., and Sen S. Alteration of cardiac collagen phenotypes in hypertensive hypertrophy: role of blood pressure. J. Mol. Cell. Cardiol. 25 2 (1993) 185-196
15. Saidenberg-Kermanac'h N., Cohen-Solal M., Bessis N., De Vernejoul M.C., and Boissier M.C. Role for osteoprotegerin in rheumatoid inflammation. Joint Bone Spine 71 1 (2004) 9-13 Review
16. Schoppet M., Sattler A.M., Schaefr J.R., Herzum M., Maisch B., and Hofbauer L.C. Increased osteoprotegerin serum levels in men with coronary artery disease. J. Clin. Endocrinol. Metab. 88 3 (2003) 1024-1028
17. Schoppet M., Ruppert V., Hofbauer L.C., Henser S., Al-Fakhri N., Christ M., Pankuweit S., and Maisch B. TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 38 4 (2005) 1745-1750
18. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ. Res. 90 (2002) 520-530
19. Ueland T., Yndestad A., Oie E., Geir F., Halvorsen B., Froland S.S., Simonsen S., Christensen G., Gullestad L., and Aukrust P. Dysregulated osteoprotegerin/RANK Ligand/RANK axis in clinical and experimental heart failure. Circulation 111 19 (2005) 2461-2468
20. Walsh K.B. Adenoviral-mediated expression of dihydropyridine-insensitive L-type calcium channels in cardiac ventricular myocytes and fibroblasts. Eur. J. Pharmacol. 565 1-3 (2007) 7-16
21. Weber K.T. Cardiac interstitium in health and disease: the fibrillar collagen network. J. Am. Coll. Cardiol. 13 (1989) 1637-1652
22. Wei L., Wei-Min L., Cheng G., and Bao-Guo Z. Upregulation of CD4 + CD25+ T lymphocyte by adenovirus-mediated gene transfer of CTLA4Ig fusion protein in experimental autoimmune myocarditis. Autoimmunity 39 4 (2006) 289-298
23. Wittrant Y., Theoleyre S., Couilaud S., Dunstan C., Heymann D., and Redini F. Regulation of osteoclast protease expression by RANKL. Biochem. Biophys. Res. Commun. 310 (2003) 774-778
24. Yu Q., Watson R.R., Marchalonis J.J., and Larson D.F. A role for T lymphocytes in mediating cardiac diastolic function. Am. J. Physiol., Heart Circ. Physiol. 289 (2005) H643-H651